Avoro Capital Advisors LLC purchased a brand new place in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) within the 2nd quarter, HoldingsChannel studies. The institutional investor purchased 1,839,138 shares of the corporate’s inventory, valued at roughly $43,238,000. Spyre Therapeutics accounts for about 0.6% of Avoro Capital Advisors LLC’s portfolio, making the inventory its twenty ninth largest place.
A number of different hedge funds additionally just lately added to or diminished their stakes in SYRE. Amalgamated Financial institution bought a brand new place in Spyre Therapeutics within the second quarter valued at $28,000. Quest Companions LLC acquired a brand new stake in shares of Spyre Therapeutics throughout the 2nd quarter valued at about $36,000. SG Americas Securities LLC bought a brand new place in shares of Spyre Therapeutics within the 2nd quarter valued at about $130,000. Carlyle Group Inc. acquired a brand new place in Spyre Therapeutics within the 2nd quarter value about $227,000. Lastly, Profund Advisors LLC bought a brand new place in Spyre Therapeutics throughout the second quarter value roughly $296,000. 80.39% of the inventory is owned by hedge funds and different institutional traders.
Wall Avenue Analyst Weigh In
SYRE has been the subject of quite a few analysis analyst studies. Wedbush started protection on shares of Spyre Therapeutics in a analysis be aware on Wednesday, September 4th. They issued an “outperform” score and a $45.00 value goal on the inventory. Evercore ISI assumed protection on shares of Spyre Therapeutics in a report on Tuesday, July sixteenth. They set an “outperform” score on the inventory. Ten analysts have rated the inventory with a purchase score, Based on MarketBeat.com, the inventory at present has a median score of “Purchase” and a consensus value goal of $43.43.
Test Out Our Newest Inventory Report on Spyre Therapeutics
Spyre Therapeutics Inventory Efficiency
Shares of Spyre Therapeutics inventory opened at $30.17 on Monday. The enterprise’s 50 day shifting common value is $27.99 and its 200 day shifting common value is $31.89. The corporate has a market cap of $1.22 billion, a price-to-earnings ratio of -0.42 and a beta of two.92. Spyre Therapeutics, Inc. has a one 12 months low of $8.43 and a one 12 months excessive of $47.97.
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) final introduced its quarterly earnings information on Wednesday, August seventh. The corporate reported ($0.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.04. On common, analysts predict that Spyre Therapeutics, Inc. will submit -3.68 EPS for the present fiscal 12 months.
Spyre Therapeutics Firm Profile
Spyre Therapeutics, Inc, a preclinical stage biotechnology firm, focuses on growing therapeutics for sufferers residing with inflammatory bowel illness (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the therapy of IBD (ulcerative colitis and Crohn’s illness).
Featured Tales
Need to see what different hedge funds are holding SYRE? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report).
Obtain Information & Rankings for Spyre Therapeutics Day by day – Enter your electronic mail deal with under to obtain a concise day by day abstract of the newest information and analysts’ rankings for Spyre Therapeutics and associated firms with MarketBeat.com’s FREE day by day electronic mail e-newsletter.